Literature DB >> 8015373

Reduction in dopamine transporter mRNA after cessation of repeated cocaine administration.

C Cerruti1, N S Pilotte, G Uhl, M J Kuhar.   

Abstract

Male, Lewis rats were treated intravenously for 2 weeks with saline or cocaine using a dose and injection schedule that is similar to the doses and patterns of cocaine intake in self-administration studies. Ten days after cessation of treatment, dopamine transporter binding levels were decreased in the nucleus accumbens but not in the striatum. In situ hybridization studies revealed decreases in dopamine transporter mRNA that were restricted to cells of the interfascicular and caudal linear nuclei; these dopaminergic cell groups, found in the ventral tegmentum, project to the nucleus accumbens and other limbic areas. Other dopaminergic cell groups in midbrain which project mainly to other areas did not show a decrease in mRNA. These results indicate that gene expression can be altered many days after withdrawal from cocaine, and provide an example of transporter regulation by a change in gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8015373     DOI: 10.1016/0169-328x(94)90040-x

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  15 in total

1.  Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathways.

Authors:  Paul D Shilling; Richard L Saint Marie; Jody M Shoemaker; Neal R Swerdlow
Journal:  Biol Psychiatry       Date:  2008-02-20       Impact factor: 13.382

2.  Availability of dopamine and serotonin transporters in opioid-dependent users--a two-isotope SPECT study.

Authors:  Tzung Lieh Yeh; Kao Chin Chen; Shih-Hsien Lin; I Hui Lee; Po See Chen; Wei Jen Yao; Sheng-Yu Lee; Yen Kuang Yang; Ru-Band Lu; Mei-Hsiu Liao; Nan-Tsing Chiu
Journal:  Psychopharmacology (Berl)       Date:  2011-09-01       Impact factor: 4.530

3.  Food restriction enhances the central rewarding effect of abused drugs.

Authors:  S Cabeza de Vaca; K D Carr
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

Review 4.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

5.  Influence of cocaine on the JAK-STAT pathway in the mesolimbic dopamine system.

Authors:  M T Berhow; N Hiroi; L A Kobierski; S E Hyman; E J Nestler
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 6.  Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addiction.

Authors:  Natalie A Hadad; Lori A Knackstedt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-06       Impact factor: 4.530

7.  Maternal "junk-food" feeding of rat dams alters food choices and development of the mesolimbic reward pathway in the offspring.

Authors:  Z Y Ong; B S Muhlhausler
Journal:  FASEB J       Date:  2011-03-22       Impact factor: 5.191

8.  Transcriptomic profiling of the ventral tegmental area and nucleus accumbens in rhesus macaques following long-term cocaine self-administration.

Authors:  Eric J Vallender; Dharmendra B Goswami; Nina M Shinday; Susan V Westmoreland; Wei-Dong Yao; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2017-03-18       Impact factor: 4.492

9.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.

Authors:  Li Xu; Wen-Fang Chen; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.